Celon Pharma (CLN) Q4 2025 earnings summary

Executive summary

• Achieved 17.9% year-over-year revenue growth to PLN 244.3m, driven by both generic and innovative segments.

• EBITDA margin improved to 8.9% from 7.3% year-over-year, despite a net loss of PLN 78.4m due to high R&D investments.

• Continued expansion of the generic portfolio, notably in cardiometabolic drugs, and advanced clinical development in innovative therapies.

• Strengthened international presence, including new production investment in Slovakia and ongoing global registration of flagship products.

Financial highlights

• Consolidated revenues rose to PLN 244.3m from PLN 207.2m year-over-year; generic segment contributed 84.4% of total sales.

• EBITDA increased 44.2% year-over-year to PLN 21.7m; EBIT loss narrowed to PLN -24.6m from PLN -36.8m.

• Net loss widened to PLN -78.4m from PLN -34.4m, mainly due to R&D costs and equity method loss from Novohale Therapeutics.

• Cash position at year-end was PLN 31m, down from PLN 75m, reflecting investment outflows.

Outlook and guidance

• Management expects continued growth in domestic sales and moderate export growth, with ongoing price erosion in generics.

• Strategic focus on expanding the innovative pipeline, especially in metabolic diseases and GLP-1 analogs.

• Further international expansion planned, including U.S. and China launches for key products within 2–3 years.